Received Jan 21, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 2 | — | — |
impending myasthenic crisis; This is a literature report for the following literature source(s). One patient who had been well controlled on prednisone monotherapy experienced progressive ptosis, diplopia and dysphagia two days after receiving his second dose of the Pfizer-BioNTech vaccine and was admitted to the hospital for impending myasthenic crisis. He was treated with plasmapheresis and had rapid initial recovery but had subsequent worsening requiring maintenance intravenous immunoglobulin (IVIg) therapy and higher prednisone dose. CONCLUSION(S): For the majority patients in our cohort (98%), SARS-CoV-2 vaccination resulted in mild side effects very similar to those reported in the pivotal vaccine trials. Two patients however did have worsening of their myasthenia gravis, with one experiencing impending myasthenic crisis requiring hospitalization and emergent plasmapheresis. This is an ongoing effort, and the total number is expected to increase by the time of presentation.; Sender's Comments: As there is limited information in the case provided, the causal association between the event myasthenia gravis crisis and the suspect drug BNT162B2 cannot be excluded. The case will be reassessed once new information is available. The impact of this report on the benefit-risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, ethics committees and investigators, as appropriate. Linked Report(s): US-PFIZER INC-202600010214 Same article/drug and different patient. ;US-PFIZER INC-202600010214 Same article/drug and different event/patient.;
Medical History/Concurrent Conditions: Myasthenia gravis